<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162680</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00015861</org_study_id>
    <nct_id>NCT02162680</nct_id>
  </id_info>
  <brief_title>An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion</brief_title>
  <official_title>An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare how well different anesthetic, or numbing, solutions
      injected under the skin work in reducing the discomfort associated with placing a catheter
      in a vein. Two different medications, lidocaine and normal saline with benzyl alcohol, have
      been found to be effective in reducing discomfort when injected under the skin just prior to
      inserting the catheter. This study compares these two solutions, and will compare the
      discomfort that occurs both with and without using these solutions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Differences in Patients' Perceptions of Pain Between Treatment Methods</measure>
    <time_frame>at pre injection, during anesthetic injection, and during catheter insertion, up to approximately 1 minute</time_frame>
    <safety_issue>No</safety_issue>
    <description>The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain. The visual analog pain score will be completed at the following time points: pre injection, during injection, and during catheter insertion.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>IV Insertion Pain</condition>
  <arm_group>
    <arm_group_label>lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1% lidocaine intradermal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bacteriostatic normal saline (BNS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bacteriostatic normal saline (BNS) injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no local anesthetic</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care practice of no local anesthetic administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% lidocaine</intervention_name>
    <arm_group_label>lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bacteriostatic normal saline (BNS)</intervention_name>
    <arm_group_label>bacteriostatic normal saline (BNS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients (aged 18 or older)

          -  admitted to a general medical or surgical unit at Durham Regional Hospital (DRH)

          -  have a physician's order for an IV

          -  are able to speak, read and understand English

          -  referred to the Vascular Access Specialty Team (VAST) at DRH for IV catheterization

        Exclusion Criteria:

          -  admission to the emergency room, pre-op unit, an outpatient unit, a psychiatric unit,
             an intensive care unit, a pre- or postnatal care unit, or labor and delivery units;

          -  history of a psychological disorder, as determined from the patient's chart;

          -  history of peripheral neuropathy, as determined by patient's chart;

          -  history of IV drug abuse, as determined from the patient's chart;

          -  decreased sensation in the arm or hands, as reported in the chart or by the patient;

          -  patient disorientation or confusion (i.e., unable to state person, place, time or
             unable to comprehend instructions for completing Visual Analog Scale);

          -  a known allergy to lidocaine or benzyl alcohol as determined from the patient's
             chart;

          -  veins that cannot be palpated and are difficult to visualize by VAST nurses;

          -  pregnancy;

          -  an order for the emergency insertion of an IV by the patient's doctor or assigned
             nurse;

          -  an IV insertion that requires the use of a catheter gauged 18 or larger

          -  severe vision impairment, as determined by the patient's inability to read the Visual
             Analogue Scale
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julia Aucoin, DNS, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>July 29, 2014</lastchanged_date>
  <firstreceived_date>June 11, 2014</firstreceived_date>
  <firstreceived_results_date>June 26, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>local anesthesia</keyword>
  <keyword>intravenous catheter</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>99 subjects consented in the study. 1 subject withdrawn from study by PI, therefore 98 subjects completed study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>no Local Anesthetic</title>
          <description>usual care practice of no local anesthetic administration</description>
        </group>
        <group group_id="P2">
          <title>Lidocaine</title>
          <description>1% lidocaine intradermal injection
1% lidocaine</description>
        </group>
        <group group_id="P3">
          <title>Bacteriostatic Normal Saline (BNS)</title>
          <description>bacteriostatic normal saline (BNS) injection
bacteriostatic normal saline (BNS)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>no Local Anesthetic</title>
          <description>usual care practice of no local anesthetic administration</description>
        </group>
        <group group_id="B2">
          <title>Lidocaine</title>
          <description>1% lidocaine intradermal injection
1% lidocaine</description>
        </group>
        <group group_id="B3">
          <title>Bacteriostatic Normal Saline (BNS)</title>
          <description>bacteriostatic normal saline (BNS) injection
bacteriostatic normal saline (BNS)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="32"/>
                <measurement group_id="B4" value="98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>18 and older</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="32"/>
                <measurement group_id="B4" value="98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="55"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="16"/>
                <measurement group_id="B4" value="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="21"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="59"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="15"/>
                <measurement group_id="B4" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="2"/>
                <measurement group_id="B4" value="9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="33"/>
                <measurement group_id="B2" value="33"/>
                <measurement group_id="B3" value="32"/>
                <measurement group_id="B4" value="98"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Patients' Perceptions of Pain Between Treatment Methods</title>
        <description>The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain. The visual analog pain score will be completed at the following time points: pre injection, during injection, and during catheter insertion.</description>
        <time_frame>at pre injection, during anesthetic injection, and during catheter insertion, up to approximately 1 minute</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>no Local Anesthetic</title>
            <description>usual care practice of no local anesthetic administration</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine</title>
            <description>1% lidocaine intradermal injection
1% lidocaine</description>
          </group>
          <group group_id="O3">
            <title>Bacteriostatic Normal Saline (BNS)</title>
            <description>bacteriostatic normal saline (BNS) injection
bacteriostatic normal saline (BNS)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="33"/>
                  <measurement group_id="O3" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Differences in Patients' Perceptions of Pain Between Treatment Methods</title>
            <description>The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain. The visual analog pain score will be completed at the following time points: pre injection, during injection, and during catheter insertion.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Pain pre injection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.015" spread="0.87"/>
                  <measurement group_id="O2" value="0" spread="0"/>
                  <measurement group_id="O3" value="0" spread="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain during catheter insertion</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.909" spread="2.127"/>
                  <measurement group_id="O2" value="0.197" spread="0.499"/>
                  <measurement group_id="O3" value="0.609" spread="1.674"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain during study drug injection</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Participants did not receive a study drug injection.</measurement>
                  <measurement group_id="O2" value="0.727" spread="1.039"/>
                  <measurement group_id="O3" value="0.781" spread="1.263"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>no Local Anesthetic</title>
          <description>usual care practice of no local anesthetic administration</description>
        </group>
        <group group_id="E2">
          <title>Lidocaine</title>
          <description>1% lidocaine intradermal injection
1% lidocaine</description>
        </group>
        <group group_id="E3">
          <title>Bacteriostatic Normal Saline (BNS)</title>
          <description>bacteriostatic normal saline (BNS) injection
bacteriostatic normal saline (BNS)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Julia Aucoin, DNS</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>1 919 613 6406</phone>
      <email>julia.aucoin@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
